Aclaris Therapeutics ACRS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.37M+6.9% | $7.83M-50.3% | $15.74M-6.2% | $16.79M-5.6% | $17.78M-5.0% | ||
| $1.98M-5.3% | $2.09M-7.6% | $2.26M-4.9% | $2.38M-4.4% | $2.49M-10.9% | ||
| $56.72M+7.7% | $52.65M+16.8% | $45.09M+18.6% | $38.02M+7.6% | $35.33M+5.2% | ||
| $22.58M+2.7% | $21.97M+2.9% | $21.35M-3.5% | $22.13M+2.9% | $21.5M-3.2% | ||
| $428K-5.7% | $454K-8.3% | $495K-12.2% | $564K-18.5% | $692K-14.3% | ||
| $88.85M+5.5% | $84.2M-50.2% | $169.06M+3.4% | $163.43M+2.9% | $158.86M-1.1% | ||
| -$80.48M-5.4% | -$76.38M+50.2% | -$153.32M-4.6% | -$146.64M-3.9% | -$141.08M+0.6% | ||
| -961.9%+14.0pp | -975.9%-2.0pp | -973.9%-101pp | -873.4%-79.8pp | -793.6%-35.4pp | ||
| $6.99M-8.5% | $7.64M-5.8% | $8.11M-2.1% | $8.28M+1.8% | $8.13M+2.2% | ||
| $10.82M-5.5% | $11.45M-1.6% | $11.64M-2.9% | $11.99M+10.2% | $10.88M+10.2% | ||
| -$69.66M-7.3% | -$64.92M+54.2% | -$141.68M-5.2% | -$134.65M-3.4% | -$130.21M+1.4% | ||
| -832.6%-3.0pp | -829.6%+70.4pp | -900%-98.0pp | -802%-69.6pp | -732.4%-27.0pp | ||
| -$0.56-5.7% | -$0.53+66.5% | -$1.58-0.6% | -$1.57+1.3% | -$1.59+7.0% | ||
| -$0.56-5.7% | -$0.53+66.5% | -$1.58-0.6% | -$1.57+1.3% | -$1.59+7.0% | ||
| 496.6M+1.3% | 490.2M+10.2% | 444.9M+13.0% | 393.6M+15.0% | 342.4M+17.6% | ||
| 496.6M+1.3% | 490.2M+10.2% | 444.9M+13.0% | 393.6M+15.0% | 342.4M+17.6% | ||
| —— | $2.3M— | —— | —— | —— | ||
| -$70.07M-8.8% | -$64.41M+54.5% | -$141.51M-5.8% | -$133.71M-3.3% | -$129.41M+1.9% | ||
| —— | —— | —— | —— | —— | ||
| $5.58M+7.4% | $5.19M-59.6% | $12.85M+1.2% | $12.7M+0.4% | $12.65M-0.2% | ||
| -$412K-180% | $513K— | —— | —— | —— | ||
| -$412K-180% | $513K— | —— | —— | —— | ||
| $8.37M+6.9% | $7.83M-50.3% | $15.74M-6.2% | $16.79M-5.6% | $17.78M-5.0% | ||
| $3.84M+0.6% | $3.82M+8.1% | $3.53M-4.8% | $3.71M— | —— | ||
| -$80.48M-5.4% | -$76.38M+50.2% | -$153.32M-4.6% | -$146.64M-3.9% | -$141.08M+0.6% | ||
| -$80.06M-5.4% | -$75.92M+50.3% | -$152.82M-4.6% | -$146.07M-4.0% | -$140.39M+0.5% | ||
| -$80.06M-5.4% | -$75.92M+50.3% | -$152.82M-4.6% | -$146.07M-4.0% | -$140.39M+0.5% | ||
| -956.8%+13.3pp | -970.1%+0.7pp | -970.8%-101pp | -870.1%-80.4pp | -789.7%-35.9pp | ||
| -$80.48M-5.4% | -$76.38M+50.2% | -$153.32M-4.6% | -$146.64M-3.9% | -$141.08M+0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aclaris Therapeutics's revenue?
- Aclaris Therapeutics (ACRS) generated $8.4M in revenue over the trailing twelve months, down 52.9% year over year.
- Is Aclaris Therapeutics profitable?
- Aclaris Therapeutics is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -832.6% net margin.
- What are Aclaris Therapeutics's profit margins?
- Gross margin is 76.3% and operating margin is -961.9%, with a -832.6% net margin.
- What is Aclaris Therapeutics's earnings per share?
- Aclaris Therapeutics's diluted EPS over the trailing twelve months is $-0.56.
- Where does Aclaris Therapeutics's income statement data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
